2024 年全球視網膜藥物市場：地圖樣萎縮及其他非滲出性視網膜疾病

本報告研究了全球視網膜藥物市場，概述了非滲出性視網膜疾病，並預測了市場成長的五年情況、未來的主要趨勢以及市場競爭對手的概況。

目錄

• 關於非滲出性視網膜疾病及其危險因子的思考
• 這些疾病的診斷和治療
• 視網膜醫學與視網膜專家的觀點
• 已上市治療非滲出性視網膜疾病的藥物和生物製劑
• 正在研發中的試驗性藥物
• 開發和銷售非滲出性視網膜疾病藥物的公司簡介，以及其他擁有臨床前項目的公司列表

What's New:

This first-edition "2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases" estimates the prevalence of nonexudative retinal diseases and forecasts the treatment market by region for complement inhibitors, gene therapies, and more.

The report examines clinical-stage drug-development programs, reviews the development stages of drug- delivery platforms, and analyzes trends in doctor interest in complement inhibitors in both the United States and Western Europe, as well as patient dosing with complement inhibitors in the United States.

The "2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases" analyzes the market for complement inhibitors, gene therapies, antioxidants, sustained-release devices, and other treatments for geographic atrophy, dry AMD, and additional nonexudative retinal diseases. The report discusses important trends, analyzes key factors for future market success, examines disease prevalence, reviews patient economics and reimbursement, and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 19 competitors are profiled, with discussion of their products, strategic market position, background, and outlook.

Contents:

This report explores a variety of topics intended to provide depth and context to the reader's understanding of market dynamics in this ophthalmic pharmaceutical segment. Our coverage includes:

• Discussions of nonexudative retinal diseases and their risk factors.
• Diagnosis and treatment of these diseases.
• A global view of retinal care and retina specialists.
• Pharmaceuticals and biologics in the marketplace for nonexudative retinal disease.
• Investigational agents in the development pipeline.
• Profiles of companies developing and marketing nonexudative retinal disease pharmaceuticals, plus a listing of additional companies with preclinical programs